Online inquiry

IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ7235MR)

This product GTTS-WQ7235MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets STAB1 gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_015136.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	23166
UniProt ID	Q9NY15

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7235MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15003MR	IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	SJ25C1 scFv-28Z CAR
GTTS-WQ3196MR	IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	ARENEGYR
GTTS-WQ12404MR	IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	NI-0401
GTTS-WQ9865MR	IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	K7153A
GTTS-WQ8944MR	IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	IL2 fused to diphteria toxin
GTTS-WQ8129MR	IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	HH1
GTTS-WQ12058MR	IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	MNRP1685A
GTTS-WQ14590MR	IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	SAR-650984

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST